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Abstract
We previously reported that some ATP competitive protein kinase C (PKC) inhibitors are either competitive or
uncompetitive inhibitors with respect to substrate peptides. In this report, we demonstrate how the interactions between
PKC and inhibitors change PKC activation kinetics. A substrate competitive inhibitor, bisindolylmaleimide I, targets activated
PKC and stabilizes PKC in the activated conformation. This leads to transient activation and prolonged deactivation of PKC in
the presence of bisindolylmaleimide I. In contrast, an uncompetitive substrate inhibitor, bisindolylmaleimide IV, targets
quiescent PKC and stabilizes PKC in the quiescent conformation, which generates slower activation and suppressed
translocation upon activation of PKC.
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Introduction
ATP competitive kinase inhibitors have been widely used to
identify signaling pathways. In some cases, however, pharmaco-
logical observations do not support the biochemical data. One
example is the acetylcholine induced suppression of the M-type
potassium channel [1,2] It has been known that this regulation
involves protein kinase C (PKC) activation [3,4,5]. However, some
PKC inhibitors do not prevent the suppression of the M-current
induced by muscarinic agonists, which once led to an exclusion of
PKC from the list of candidate mediators [2,6,7]. We found that
this discrepancy is due to a PKC associating protein, AKAP79/
150, which tethers PKC in the M-channel complex [4]. We
demonstrated that AKAP79/150 bound PKC cannot interact with
some PKC inhibitors, such as bisindolylmaleimide I (BIS I), since
the pseudosubstrate-like domain in the PKC binding domain of
AKAP79/150 competes with BIS I binding [8]. Through this
study, we identified BIS I as a competitive inhibitor with respect to
substrate peptides. In addition, we found that a related molecule,
BIS IV, is an uncompetitive inhibitor for the substrate peptide.
These results suggest that ATP competitive PKC inhibitors can
modify how PKC interacts with substrate peptides.
Potential interactions between substrate peptides and ATP
competitors are also suggested by crystal structure studies. To date,
several crystal structures of PKC-inhibitor complexes have been
solved [9,10,11,12]. These analyses demonstrated that such ATP
competitor molecules make hydrogen bonds with residues located
in the substrate recognition groove. Thus, the structural
information is consistent with a hypothesis that some PKC
inhibitors compete not only with ATP but also with substrate
peptides or pseudosubstrates. However, how ATP competitive
kinase inhibitors interact with the pseudosubstrate domain remains
unknown.
The pseudosubstrate domain governs the activation status of
many serine/threonine kinases [13]. PKC is a typical example of
such kinases [14,15]. In the quiescent state, the pseudosubstrate
covers the catalytic site so that no substrate proteins can be
phosphorylated. Upon activation, a conformational change
uncovers the catalytic site from the pseudosubstrate domain. This
allows substrate proteins to enter the catalytic site for phosphor-
ylation.
In this paper, we investigate functional consequences of the
interaction between the intramolecular pseudosubstrate domain of
PKC and ATP competitive inhibitors. We show that the primary
target for BIS I is activated PKC while BIS IV targets quiescent
PKC. We demonstrate that these different state-dependent
inhibitions change the activation kinetics of PKC and stabilize
PKC in certain conformations within the cellular environment.
Results
Time-dependent changes in potencies of BIS compounds
Bisindolylmaleimide I (BIS I) and bisindolylmaleimide IV (BIS
IV) are structurally very similar PKC inhibitors (Fig. 1A).
However, a crystal structure solved by others [11] and our
molecular model show that BIS I interacts with the key substrate
recognition residue, D470 [16], while BIS IV fits into the ATP
binding pocket without occupying the substrate recognition
groove (Fig. 1A). To examine the functional consequences for
this difference, we measured cellular PKC activity using the
cytoplasmic version of C kinase activity reporter, (CKAR), a
fluorescence resonance energy transfer (FRET) based fluorescent
probe [17]. CKAR was expressed in Chinese hamster ovary cells
stably expressing the human m1 muscarinic acetylcholine
receptor, CHO hm1 cells [8]. Upon application of 3 mM
oxotremorine-M (oxo-M), CHO hm1 cells expressing CKAR
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within 20 sec (Fig. 1B). Preincubation with 200 nM BIS I or
1 mM BIS IV suppressed cellular PKC activities to a similar
extent (BIS I 43.963.5% vs. BIS IV 57.463.5% of the control)
(Fig. 1C and D). A higher potency of BIS I was consistent with
the described higher affinity of BIS I than BIS IV [18]. When we
Figure 1. Two BIS compounds show distinct time-dependent changes in potency affecting cellular PKC activities. (A) Molecular
structure of bisindolylmaleimide I (BIS I, left) and bisindolylmaleimide IV (BIS IV, right). Lower panels show molecular models for BIS bound PKCbII
modified from the PDB file (2I0E). Carbon (yellow), nitrogen (blue) in BIS compounds are shown as spheres. The key residue for the substrate
recognition, D470, is highlighted in pink. (B) CHO cells expressing CKAR were stimulated with 3 mM oxotremorine-M (oxo-M) at t=0. Fluorescent
signals from cells from the CFP channel are shown (far left). Oxo-M application induces phosphorylation of CKAR and a change in the CFP/YFP
fluorescent ratio of the CKAR probe, shown as pseudocolor images. Images from indicated times are shown. (C) Cellular PKC activities in the presence
(blue) or absence (white) of 200 nM BIS I. The black box indicates the presence of oxo-M. (D) Cellular PKC activity in the presence (orange) or absence
(white) of 1 mM BIS IV. (E) Relative PKC activity in the presence of BIS I (blue) or BIS IV (orange) normalized to the PKC activity without inhibitors
(white) derived from (C) and (D).
doi:10.1371/journal.pone.0026338.g001
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compounds, we realized that the PKC responses from both BIS I
and BIS IV treated cells were distorted rather than a miniature of
the control responses. To further analyze this kinetic change, we
compared relative PKC activities for BIS I and BIS IV treated
cells (Fig. 1E). Relative PKC activities showed that BIS I
gradually gained in potency, as indicated by a higher PKC
activity at 6 sec than at 60 sec after activation (58.964.5% vs.
45.163.1% of the control, p,0.001). This change in the presence
of BIS I was best fit with an exponential decay with a time
constant (t)o f8 . 2 60.3 sec. On the other hand, BIS IV gradually
lost its potency; relative PKC activity was lower at 6 sec
(35.562.5%) than at 60 sec after stimulation (58.363.2%,
p,0.001). This increase in PKC activity was best fit with a
single exponential association with t of 25.561.3 sec.
Activation states and potencies for BIS compounds
To further examine whether the activation status of PKC
changes BIS binding, we compared sensitivity to BIS I between
preactivated PKC and quiescent PKC (Fig. 2A, B and C).
Preactivation of PKC with 100 nM phorbol 12,13-dibutyrate
(PDBu) promoted PKC inhibition by 200 nM BIS I (preactivated
condition, 36.862.5% vs. quiescent condition, 63.067.5% of the
control responses, p,0.01) (Fig. 2A and B). To clarify the
mechanism for this facilitation, we measured inhibition kinetics for
the two conditions by varying the incubation times with BIS
compounds with or without preactivation. In the preactivated
condition, BIS I reached its maximal inhibition within 60 sec
incubation (Fig. 2C). This change was best fit with a single
exponential decay with t of 16.462.6 sec. In contrast, when BIS I
was added in the quiescent condition, it required more than 4 min
to reach the plateau inhibition, t=120.6622.1 sec. On the other
hand, 1 mM BIS IV inhibited oxo-M responses equally in both
quiescent and preactivated conditions (Fig. 2D and E). Interest-
ingly, BIS IV suppressed PKC within 1 min in both conditions,
although the plateau inhibition was less than that of BIS I (Fig. 2F).
In other words, neither inhibition kinetics nor potency of BIS IV
were changed by preactivation of PKC (preactivation,
t=12.966.4 sec vs. control, t=13.864.7 sec).
The pseudosubstrate domain and BIS binding
If the pseudosubstrate domain interferes with the PKC-BIS I
binding, then BIS I should interfere with the binding of the
pseudosubstrate domain to the substrate recognition site. To test
this, we fused the pseudosubstrate domain with GFP, Psd-GFP,
and examined its binding to V5 tagged PKCbII, PKCbII-V5, by
immunoprecipitation. Since synthesized pseudosubstrate peptides
have been used as PKC inhibitors [19], Psd-GFP should replace
the endogenous pseudosubstrate domain at the substrate recogni-
tion site in PKCbII. However, we could not detect PKCbII in Psd-
GFP precipitates (Fig. 3A). We suspected that, in the non-activated
condition, the intramolecular pseudosubstrate domain competes
Figure 2. Activation status of PKC changes the inhibition kinetics of BIS I but not BIS IV. (A) Oxo-M responses with (closed circles) or
without (open circles) BIS I in the quiescent condition. The boxes indicate the presence of 200 nM BIS I (grey) and 3 mM oxo-M (black). (B) Oxo-M
responses with (closed circles) or without (open circles) BIS I in the preactivated condition. Cells were treated sequentially with 100 nM phorbol
12,13-dibutyrate (PDBu) (open box), 200 nM BIS I (grey box), and 3 mM oxo-M (black box). (C) Relative peak oxo-M responses from experiments
similar to (A) and (B) with various incubation times with BIS I. Peak oxo-M responses under various BIS I incubation times are normalized to the peak
response without BIS I treatment (t=0). For instance, (A) represents two data points for the PDBu(–) condition, t=0 min (no inhibitor, n=19) and
t=5 min (BIS I, n=14). (B) represents two data points for the PDBu(+) condition, t=0 (no inhibitor, n=15) and t=5 min (BIS I, n=15). Preactivation
with PDBu (closed circles) facilitates PKC inhibition by BIS I compared to no PDBu (open circles). (D) Oxo-M responses with (closed circles) or without
(open circles) 1 mM BIS IV in the quiescent condition. The control is the same as in (A). (E) Oxo-M responses with (closed circles) or without (open
circles) 1 mM BIS IV in the preactivated condition. The control is the same as in (B). (F) Time course of relative peak oxo-M responses showing
inhibition kinetics of BIS IV for preactivated PKC (closed circles) and the control (open circles) from experiments similar to (D) and (E) with various
incubation times with BIS IV. Relative peak oxo-M responses with various incubation time with BIS IV are calculated using response at t=0 as a
reference. Panel (D) represents two data points for the PDBu(–) condition, t=0 (no inhibitor, n=19) and t=5 min (BIS IV, n=15). Panel (E) represents
two data points for the PDBu(+) condition, t=0 (no inhibitor, n=15), and t=5 min (BIS IV, n=9).
doi:10.1371/journal.pone.0026338.g002
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PKCbII lacking the pseudosubstrate domain, (D2-31)PKCbII. As
expected, (D2-31)PKCbII coprecipitated with Psd-GFP in the
non-activated condition. Addition of ATP further enhanced
association between Psd-GFP and (D2-31)PKCbII, which is
consistent with the evidence that ATP is a natural stabilizer for
the pseudosubstrate-kinase interaction in some kinases
[14,20,21,22]. When Psd-GFP immunoprecipitation was per-
formed in the presence of BIS I, coprecipitated PKCbII was
greatly reduced (Fig. 3A). In contrast, addition of BIS IV
promoted the association to an extent similar to that observed in
the presence of ATP.
Since the above experiments used a deletion mutant, we next
intended to confirm these effects of BIS compounds using wild-
type PKCbII. Since our immunoprecipitation in the non-activated
condition did not show stable association between PKCbII and
Psd-GFP, we tested the interaction in the presence of a PKC
activator. Activation of PKC should remove the intramolecular
pseudosubstrate domain from its catalytic site, which would allow
Psd-GFP to bind PKC. To this end, purified PKCbII was first
treated with PDBu together with BIS I or BIS IV, then Psd-GFP
bound resin was added to test PKC binding. In this preactivated
condition, we could detect PKCbII in Psd-GFP precipitate as
expected (Fig. 3B). When BIS I was included in the binding buffer,
Figure 3. BIS compounds change how the pseudosubstrate domain interacts with PKC. (A) Immunoprecipitation from cell lysates
expressing the pseudosubstrate domain fused with GFP (Psd-GFP) and V5 tagged wild-type PKCbII or the pseudosubstrate domain deleted PKCbII,
(D2-31)PKCbII. The binding conditions are indicated. (B) In vitro binding between Psd-GFP and purified PKCbII in the presence of PDBu. Lower panel
shows quantification from independent experiments. (C) Thermal stability of purified PKCbII in indicated conditions. Four independent experiments
of triplicates are summarized. (D) Subcellular localization of CFP tagged PKCbII, PKCbII-CFP. Epifluorescent (EpiF) and TIRF (TIRF) images were
collected sequentially from the same cell. Focal application of 300 nM oxo-M induced translocation of PKCbII-CFP, which was terminated by 100 mM
pirenzepine (pzp). (E) Quantification of PKCbII-CFP localization by TIRF intensity from control (open circles), 5 mM BIS I (closed circles) or 5 mM BIS IV
(grey triangles) treated cells. Application of oxo-M (black box) and pirenzepine (pzp, open box) are indicated. (F) Scaled time courses from (E)
showing the deactivation process after application of pirenzepine. (G) Effects of BIS compounds on membrane location of activated PKCbII-CFP. The
boxes indicate the presence of 100 nM PDBu (white) and BIS compounds (grey). No inhibitor (open circles), 5 mM BIS I (closed circles), 5 mM BIS IV
(grey triangles) are indicated. (H) PDBu induced translocation of 5 mM BIS IV pretreated cells (grey triangles). No inhibitor control (open circles) is the
same as in panel (G). (I) Immunoblots of PKCa/b and tubulin after two-hour treatments with 5 mM BIS I and 5 mM BIS IV. Tubulin is shown as a loading
control.
doi:10.1371/journal.pone.0026338.g003
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the association of Psd-GFP and PKCbII. In both series of
experiments using (D2-31)PKCbII or wild-type PKCbII, BIS I
interfered with binding of Psd-GFP to PKC. In contrast, BIS IV
facilitated binding of Psd-GFP to PKC. This facilitation of the
pseudosubstrate-catalytic site association by BIS IV is consistent
with the fact that BIS IV is an uncompetitive inhibitor with respect
to substrate peptides, which stabilizes the substrate peptide-PKC
complex. These results also suggest that BIS IV promotes
interaction between the pseudosubstrate and the catalytic site,
which may increase the energy required for displacement of the
pseudosubstrate from the catalytic cleft. To test this, we performed
a thermal stability assay [23]. PKC activities were measured after
incubation at 37uC for 30 min and compared with reference
samples kept on ice. Wild-type PKCbII showed only 13.760.7%
(n=4) of PKC activity after a 37uC incubation (Fig. 3C). Inclusion
of 1 mM BIS IV during the incubation improved PKC stability.
ATP showed similar stabilization in a higher concentration
(Fig. 3C).
These results suggest that BIS compounds modify the
interaction between the pseudosubstrate and the catalytic site in
distinct ways: BIS I repels the pseudosubstrate domain from the
catalytic site, while BIS IV stabilizes the association of the
pseudosubstrate domain and the catalytic site. Our new results
suggest that BIS compounds can stabilize PKC either in the
activated state or in the quiescent state depending on their
molecular structures. The next question is whether such
stabilizations occur within the cellular environment.
BIS compounds and PKC translocation
To address this question, we measured the activation and
deactivation processes of PKC using CFP tagged PKCbII, PKC-
CFP. Conventional PKC is a unique kinase in that its
conformational changes can be detected as a change in subcellular
localization [15]. In the quiescent condition, conventional PKC
localizes in the cytoplasm. Upon activation, PKC translocates to
the plasma membrane. We utilized this unique feature of
conventional PKC. To observe both the activation and the
deactivation processes, we first stimulated cells with oxo-M for
1 min and then added a muscarinic receptor antagonist,
pirenzepine, to terminate stimulation. We lowered the concentra-
tion of oxo-M to eliminate latency in the recovery process of PKC
after adding pirenzepine. When PKC-CFP was expressed in CHO
hm1 cells, PKC-CFP localized in the cytoplasm in the resting
condition as expected (Fig. 3D). Application of oxo-M induced
translocation of PKC-CFP to the plasma membrane. This
translocation was clearly visible by epi-fluorescent microscopy,
but quantification of this translocation was difficult (Fig. 3D). Total
internal reflection fluorescent (TIRF) microscopy helped overcome
this problem since translocation is directly converted into intensity
of TIRF signals (Fig. 3D) [24]. In this setting, application of oxo-M
induced a 2.960.1-fold increase in the TIRF signal at the 10 sec
time point (Fig. 3E). Translocation was suppressed by 5 mM BIS
IV throughout oxo-M application (p,0.0001), which supports our
hypothesis that BIS IV stabilizes the quiescent state of PKC. For
instance, the 10 sec time point showed a 2.260.1-fold increase
with BIS IV. In contrast, treating cells with 5 mM BIS I had minor
effects on the activation process; 2.660.1-fold increase (p,0.01) at
the 10 sec point, which became indistinguishable from the control
after 30 sec. These changes in translocation were not derived from
changes in amount of PKC protein due to BIS treatments since
immunoblots verified equivalent PKC amounts after 2 hr of BIS
treatments (Fig. 3I): 126616% (n= 3) for BIS I, 121618% (n =
3) for BIS IV, respectively.
On the other hand, BIS I did affect the deactivation process. In
the control condition, PKC-CFP restored its cytoplasmic locali-
zation after application of 100 mM pirenzepine with t of
12.160.6 sec (Fig. 3F). In the presence of BIS I, however, the
deactivation process was delayed (t=32.360.7 sec, p,0.0001).
Treatment with BIS IV had little effect on the deactivation
process, t=17.761.1 sec (p.0.05). These results suggest that BIS
IV can stabilize PKC in the quiescent conformation. We
wondered whether BIS IV could switch activated PKC to the
quiescent conformation in the presence of PDBu. To address this,
we first activated PKC-CFP by PDBu and then added BIS
compounds to see whether or not they affect membrane location
of PKC-CFP. Application of PDBu induced slower translocation
of PKC-CFP than oxo-M induced translocation, which is
consistent with the slower activation of kinase activity (Fig. 2B).
After 2 min incubation with PDBu, 5 mM BIS I or 5 mM BIS IV
was applied (Fig. 3G). BIS I did not affect the membrane
localization of activated PKC-CFP; 7.269.7% reduction com-
pared to no inhibitor control at t=3 min (p.0.05). BIV IV
induced a small reduction of membrane PKC-CFP, 23.266.4%
reduction when compared to no inhibitor control (t=3 min,
p,0.01). However, this reduction would be better attributed to
prevention of further activation of PKC since the TIRF signal
remained unchanged after application of BIS IV (t=2 min vs.
t=3 min, p.0.05). We further tested how pretreatment with BIS
IV changes PDBu induced PKC-CFP translocation. Similar to
oxo-M induced translocation, pretreatment with BIS IV showed
suppressed PDBu induced translocation (Fig. 3H, 51.069.5% of
the control at t=3 min). These results suggest that, even though
BIS IV stabilizes PKC in the quiescent state, BIS IV binding per se
is not sufficient to turn activated PKC into the quiescent state in
the presence of PDBu. Taken together, these results suggest that
BIS compounds can stabilize PKC in either the quiescent state or
the activated state in living cells depending on how the compounds
interact with the pseudosubstrate domain in the cellular
environment.
State-dependent inhibition of staurosporine and its
derivative
To test whether these effects are specific to BIS compounds or
represent common phenomena for ATP competitive inhibitors, we
performed a similar series of experiments using staurosporine and
K-252c. Staurosporine is a prototypical molecule for ATP
competitors and is a wide spectrum kinase inhibitor that shows
high affinity binding to most kinases. K-252c is a staurosporine
aglycone that lacks the amino group; the structural relation
between K-252c and staurosporine is analogous to that of BIS IV
and BIS I (Fig. 4A). Staurosporine treated cells showed a time-
dependent increase in potency after activation of PKC by oxo-M,
which was similar to but more prominent than for BIS I treated
cells (Fig. 4B and D). For K-252c, it required 10 mM to achieve
PKC inhibition similar to 100 nM staurosporine, which supports
that the amino group in staurosporine provides additional
interaction contributing to its high affinity (Fig. 4C). Even though
100 nM staurosporine suppressed almost all PKC activity at 4 min
after oxo-M application, it suppressed less than 50% at 10 sec after
activation (Fig. 4D). This decrease in PKC activity followed a
single exponential decay with t of 48.562.1 sec. K-252c treated
cells, on the other hand, showed a time-dependent loss of potency,
t=63.8610.9 sec (Fig. 4E). The binding of staurosporine was
facilitated by preactivation of PKC by PDBu (Fig. 4F). We
attempted to perform similar time course experiments using K-
252c. However, K-252c required more than 30 min incubation to
show inhibitory effects, which suggests that cell permeability is the
State-Dependent Inhibition of ATP Competitors
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inhibition kinetics of K-252c. On the other hand, immunoprecip-
itation experiments showed that staurosporine prevented associ-
ation between Psd-GFP and (D2-31)PKCbII, while K-252c
promoted the association (Fig. 4G). These results duplicated what
was observed with the BIS compounds and suggest that state-
dependent inhibitions are common phenomena for ATP compet-
itive inhibitors.
Discussion
In the present study, we have characterized the cellular
pharmacology of several ATP competitive PKC inhibitors. Unlike
conventional kinase assays that measure stationary activities,
FRET based live-cell imaging analyses [25] enable us to measure
real time PKC activities, which makes it optimal for analyzing the
kinetics of kinase activation and kinase inhibition. By employing
this technique, we identified that common PKC inhibitors are
state-dependent inhibitors, which target either quiescent or
activated PKC. This conclusion was derived from the following
three supportive observations.
Firstly, these PKC inhibitors showed time-dependent changes in
their potencies after activation of PKC. The time-dependent
changes for both BIS I and BIS IV were best fitted by single
exponential functions (Fig. 1), which suggests a single step
transition to a new equilibrium. Interestingly, even though BIS I
and BIS IV are structurally very similar to each other, the changes
in potency after activation of PKC were opposite; BIS I showed an
increase in potency while BIS IV exhibited a decrease in potency.
These results suggest that BIS compounds have distinct affinities
for either quiescent or activated PKC.
Secondly, BIS I preferentially inhibited preactivated PKC. This
is evidenced by higher susceptibility to inhibition of preactivated
PKC and a much faster time course to reach the plateau inhibition
in preactivated PKC (Fig. 2). In contrast, BIS IV did not show
preference for activated PKC. The key structural difference
Figure 4. State-dependent inhibition by staurosporine and K-252c. (A) The molecular structures for staurosporine (left) and staurosporine
aglycone, K-252c (right). (B) Cellular PKC responses with (closed circles) or without (open circles) 100 nM staurosporine (ST). Application of 3 mM oxo-
M (black box) is indicated. (C) Cellular PKC responses with (closed circles) or without (open circles) 10 mM K-252c. (D, E) Scaled PKC activities from (B)
and (C). (F) Inhibition kinetics measured as oxo-M responses of PKC incubated with 100 nM staurosporine for the indicated times with (closed circles)
or without (open circles) 100 nM PDBu. (G) Coimmunoprecipitation of Psd-GFP and (D2-31)PKCbII in the control or in the presence of 10 mM
staurosporine or 10 mM K-252c.
doi:10.1371/journal.pone.0026338.g004
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occupies the substrate recognition site of PKC (Fig. 1) [11,18]. We
have previously shown that BIS I is a competitive inhibitor not
only for ATP but also for the substrate peptides [8]. Hence,
competition between BIS I and the pseudosubstrate domain was
suspected for the mechanism behind the preference for activated
PKC of BIS I. Namely, the pseudosubstrate domain protects the
substrate site from BIS I in quiescent PKC since the pseudosub-
strate domain occupies the substrate recognition site in the
quiescent state. This protective effect of the pseudosubstrate
domain in the quiescent state is consistent with the slower
inhibition kinetics of BIS I observed in the quiescent condition
compared to the preactivated condition (Fig. 2C). In contrast, BIS
IV did not show such facilitation of either potency or kinetics by
preactivation of PKC. However, the time constants of BIS IV
inhibition in both conditions were similar to that of BIS I in the
preactivated condition, which suggests interference with BIS I
inhibition in the quiescent PKC rather than facilitation in the
preactivated PKC. Accordingly, our binding studies showed that
BIS I bound PKC was unable to bind the pseudosubstrate domain
(Fig. 3A and B). Collectively, these experiments suggest that the
pseudosubstrate domain bound PKC allows limited access for BIS
I, and is thus resistant to BIS I. On the other hand, BIS IV binding
did not interfere with the pseudosubstrate domain of PKC, rather
it promotes the binding. This is consistent with our previous
observation that BIS IV is an uncompetitive inhibitor with respect
to substrate peptides [8]. This mechanism indicates that BIS IV
stabilizes the interaction between the pseudosubstrate domain and
the catalytic site. Accordingly, our binding study and thermal
stability assays showed that BIS IV stabilized the interaction
between PKC and the pseudosubstrate domain (Fig. 3A, B and C).
ATP has been known to stabilize the pseudosubstrate binding to
the catalytic site [14]. Our thermal stability assay confirmed the
stabilization effect of ATP as well as BIS IV. Since BIS IV has a
higher affinity to PKC than ATP, BIS IV should have a higher
Gibbs free energy for its binding. We speculate that this higher
binding energy is an underlying mechanism for the suppression of
cellular translocation of PKC in the presence of BIS IV; the
stabilization effect of BIS IV exceeds that of the endogenous
stabilizer, ATP.
Finally, BIS I bound PKC is stabilized in the activated
conformation. This is suggested by a delayed recovery of cytosolic
localization of PKCbII-CFP after termination of the activation
signal (Fig. 3E and F). We previously demonstrated by in vitro
experiments that BIS I stabilizes PKC in the activated conforma-
tion [8]. In the present study, we observed that such stabilization
occurred in a cellular environment. This stabilization of the
activated conformation is expected from our hypothesis since BIS I
at the catalytic site prevents restoring of the interaction between
the pseudosubstrate domain and the catalytic site (i.e. the
quiescent state).
Taken together, we speculate that the binding of BIS I and the
pseudosubstrate domain to the catalytic site are mutually exclusive
(Fig. 5). If the pseudosubstrate domain binds the catalytic site, it
cannot bind BIS I, which results in BIS I resistance. In contrast, if
BIS I binds to the catalytic site, the pseudosubstrate domain
cannot bind to the catalytic site, which stabilizes PKC in the
activated state. We believe that the delayed deactivation of PKC
(Fig. 3) induced by BIS I is equivalent to the "foot-in-the-door"
effect described in state-dependent channel inhibitors [26,27]. In
short, BIS I targets the activated PKC.
On the other hand, BIS IV is an uncompetitive inhibitor with
respect to the substrate peptide [8]. We speculate that BIS IV
stabilizes the interaction between the pseudosubstrate domain and
the substrate recognition site (Fig. 5). Our thermal stability assay
showed that PKC was stabilized by BIS IV (Fig. 3C). Furthermore,
translocation experiments showed that BIS IV treated cells had a
reduced pool of PKC that could be activated, which also supports
Figure 5. Models for state-dependent inhibition and its effects on kinase activities. Schematic diagrams (top), cartoons for relevant states
of PKC (middle) and time course of PKC activities (bottom) for two types of state-dependent PKC inhibitor models. The diagram indicates inhibitor (I)
and PKC in the quiescent state (Q) and activated state (A). The cartoons show PKC with the pseudosubstrate domain (Psd) and the catalytic domain
for the corresponding states described above. Two types of inhibitors are indicated (yellow particle, blue particle). The trace with yellow circles at the
bottom shows a conceptual model of slow activation of kinases in the presence of quiescent kinase inhibitors since the inhibitors stabilize PKC in the
quiescent state. In contrast, activated PKC inhibitors bind PKC in the activated state and interfere with the deactivation process. The time lag between
PKC activation and the inhibitor binding generates the transient activation of PKC (blue circles).
doi:10.1371/journal.pone.0026338.g005
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conformation. However, it is interesting that BIS IV treated cells
did not show slower translocation, as might have been expected
from the slower kinase activation (Fig. 1E). One possible
explanation would be that the quiescent state supports the binding
of BIS IV, and that the conformation of the kinase domain
induced by inhibitor binding affects its binding to interaction
partners such as cytosolic calcium, which impairs its translocation.
When we consider the gradual loss of BIS IV potency after
activation (Fig. 1), we believe that the pseudosubstrate-BIS IV-
catalytic site association reciprocally stabilizes their interaction.
Thus, once PKC is activated, activation would break the
pseudosubstrate-BIS IV interaction to lower BIS IV affinity,
which would result in gradual loss of its potency. Taken together,
we speculate that BIS IV counteracts the conformational change
that dissociates the pseudosubstrate domain from the catalytic site,
which suppresses the translocation of PKC.
Recently, a crystal structure of full-length PKCbII has been
solved [12]. The study suggests a two-step activation process;
disengagement of the C1A from the catalytic domain, which
removes the pseudosubstrate domain from the catalytic site,
followed by unclamping of the C1B site, which induces an
allosteric change in the C-terminal NFD motif. Interestingly, the
identified crystal structure was formed without diacylglycerol, but
it did not show electron density for the pseudosubstrate domain
[12]. We wonder if BIS IV or K-252c could assist in solving the
structure of PKCbII in the quiescent conformation.
Despite the importance of state-dependent inhibition, not much
attention has been paid to this aspect for kinase inhibitors. Real
time monitoring of cellular kinase activity helped us to explore
state-dependent inhibition. The fact that these state-dependent
inhibitions were also observed for staurosporine, a wide spectrum
kinase inhibitor, suggests that state-dependent inhibition is a
common feature for ATP competitive inhibitors. In addition, we
wish to emphasize that, as a consequence of state-dependent
inhibition, kinase activity in the presence of kinase inhibitors is not
a proportional miniature of the control response (Fig. 5). This
feature is especially important for activated kinase inhibitors since
transient activation remains in the presence of this type of
inhibitor. For an example, if a pathway consists of a cascade of
reactions in such a way that phosphorylation is only required as its
trigger, then such pathway would not be fully inhibited by
activated PKC inhibitors. Namely, the transient PKC activity in
the presence of activated PKC inhibitors would be sufficient to
activate the pathway. This limited efficacy of active PKC
inhibitors due to the lag time of inhibitor binding could be an
alternative mechanism for resistance to kinase inhibitors in
addition to protection through scaffold proteins [8]. On the other
hand, activated PKC inhibition would be beneficial for therapeu-
tic purposes. Many pathogenic pathways involve constitutively
activated kinases, while normal pathways remain quiescent until
they are activated by physiological stimuli. Thus, activated kinase
inhibitors would selectively target such pathological pathways.
These state-dependent inhibitions would be a useful strategy to
target selective conditions in signaling cascades.
Materials and Methods
Expression plasmids
CKAR expression plasmid was a generous gift from Dr.
Alexandra Newton at UCSD [25]. We used the cytosolic version
of CKAR cDNA, which has been described previously [17]. Psd-
GFP was generated as follows: the oligo DNA encoding the
pseudosubstrate domain of PKCbII (forward, 59-GATCCC-
GCTTCGCCCGCAAAGGCGCCCTCCGGCAGAAGAACG-
TG-39; reverse, 59-AATTCACGTTCTTCTGCCGGAGGGCG-
CCTTTGCGGGCGAAGCGG-39) was synthesized, annealed
and ligated into pEGFP-C1 plasmid at BglII and EcoRI sites.
DNA sequencing and immunoblot verified Psd-GFP constructs.
V5 tagged PKCbII and (D2-31)PKCbII were made by PCR using
wild-type PKCbII [28] and the following primers (full-length PKC
forward, 59- CACCATGGCTGACCCGGCTGCGGGGCCGC-
CGCCG-39,( D2-31) forward, 59-CACCATGCATGAGGTCAA-
GAACCACAAATTCACCGCCCGCTTCTTCAAGCAGCCC-
39, reverse, 59-GCTCTTGACTTCGGGTTTTAAAAATTCA-
GAGTTAAC-39). PCR fragments were subcloned using the
pcDNA3.1 directional TOPO kit (Invitrogen, Carlsbad, CA). All
PCR derived fragments were confirmed by sequencing.
PKC inhibitors
Bisindolylmaleimide I, bisindolylmaleimide IV, staurosporine,
K-252c and phorbol 12,13-dibutyrate were purchased from
Sigma-Aldrich (St. Louis, MO). These compounds were dissolved
in DMSO as stock solutions and diluted at least 1:10,000 for actual
experiments. For the experiments involving steady state inhibi-
tions, cells were incubated with relevant inhibitors for between
20 min and 2 hours.
Cell culture and transfection
CHO cells stably expressing human m1 muscarinic receptor
[29] were cultured in alpha minimum essential medium, 5% fetal
bovine serum, 500 mg/ml G418 at 37uCi n5 %C O 2. HEK 293A
cells (Invitrogen, Carlsbad, CA) were cultured in Dulbecco’s
Modified Eagle’s Medium containing 10% fetal bovine serum. For
transfections, cells were grown to 30% confluence and transfected
(2 mg total plasmid DNA and 8 ml Trans-IT1 per 10 cm dish)
according to the manufacturer’s instruction (Mirus Bio, Madison,
WI).
Live-cell imaging
Fluorescence emission was acquired using an inverted micro-
scope IX-81 (Olympus, Tokyo, Japan) and ImageEM CCD
camera (Hamamatsu photonics, Shizuoka, Japan) controlled by
MetaMorph 7.6.3 (Molecular Devices, Sunnyvale, CA). The
excitation light was generated by Lambda LS (Sutter Instruments,
Novato, CA) and passed through a S436/10x or S500/20x filter.
The light intensity was reduced to 3% for 436 nm and 0.07% for
500 nm to minimize photobleaching. Dual-emission images were
obtained simultaneously through a dual-view module (Photo-
metrics, Tucson, AZ) with ET535/30m, ET480/40m emission
filters and a T505lpxr dichroic mirror (Chroma Technology,
Bellows Falls, VT). Exposure time was 100 ms; images were taken
every 1.5 s for experiments shown in Fig. 1 and 10 s for other
experiments. For total internal reflection fluorescent (TIRF)
experiments, a 445 nm diode laser (Coherent, Santa Clara, CA)
with an acousto-optic tunable filter was used with a TIRF module
(Olympus, Tokyo, Japan) equipped with IX-81. Illumination paths
between epifluorescence and TIRF were switched manually for
the sequential imaging shown in Fig. 3D. Fluorescent intensities
from each cell were background subtracted and the CFP/YFP
ratio was calculated. Since the basal CFP/YFP ratio varies
between cells, basal values before stimulation by oxo-M were
normalized and pooled for each experimental group.
Cells were cultured on round cover glasses (18 mm diameter)
and washed twice before mounting onto the microscope with a
solution consisting of 144 mM NaCl, 5 mM KCl, 2 mM CaCl2,
0.5 mM MgCl2, 10 mM glucose, 10 mM HEPES (pH 7.4). All
data are presented as mean 6 SEM.
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Transfected HEK cells were lysed with Hypotonic buffer
containing 10 mM NaCl, 1.5 mM MgCl2, 1 mM dithiothreitol,
5 mM EGTA, 10 mM HEPES (pH 7.4), 0.4% Nonidet P-40 and
complete mini protease inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN). After centrifugation at 22,000 g for 20 min at
4uC, the lysate was precleared with protein G resin, and then
immunoprecipitated with rabbit GFP antibody (Abcam, Cam-
bridge, MA), and protein G resin. Relevant samples contained
200 mM ATP or 10 mM PKC inhibitors. Psd-GFP bound resin
was washed three times with HSE buffer containing 150 mM
NaCl, 5 mM EDTA, 5 mM EGTA, 20 mM HEPES (pH 7.4),
1% Triton X-100 and analyzed by SDS-PAGE followed by
western blot.
PKC binding assay
Psd-GFP was purified from transiently transfected HEK cells by
immunoprecipitation. Transfected cells were lysed with HSE
buffer and complete mini protease inhibitor cocktail. After
centrifugation at 22,000 g for 15 min at 4uC, the lysate was
precleared with protein G resin, and then immunoprecipitated
with rabbit GFP antibody (Abcam, Cambridge, MA) and protein
G resin. Psd-GFP bound resin was washed twice with HSE buffer
followed by twice with HSE buffer containing 650 mM NaCl then
twice with HSE buffer. For the binding assay, 60 ng PKCbII
(EMD chemicals, Gibbstown, NJ) in 10 ml binding buffer was
incubated 5 min at room temperature with or without 10 mM
PKC inhibitors. Then, purified Psd-GFP attached to beads was
added and further incubated 15 min at room temperature. After
three washes with the binding buffer plus relevant PKC inhibitors,
associated proteins were analyzed by western blots using a
monoclonal antibody toward PKCb (BD bioscience, San Jose,
CA). The binding buffer consisted of 0.1% Triton X-100, 150 mM
NaCl, 100 nM PDBu, 1 mM DTT, 10 mM HEPES (pH 7.4).
PKC thermal stability assay
Aliquots of PKCbII (EMD chemicals, Gibbstown, NJ) were
prepared and incubated for 30 min at 37uC in a buffer containing
1 mM CaCl2, 1 mM dithiothreitol, 1 mM sodium orthovanadate,
25 mM b-glycorol phosphate, 20 mM MOPS (pH 7.2). Relevant
samples contained ATP and BIS IV. Reference samples were kept
on ice during the incubation. PKC kinase activity was measured
using
32P-ATP and PKC assay kit (Millipore, Billerica, MA).
Experiments were done as triplicates.
Acknowledgments
We thank Steph Skala for technical supports, Matthew Gold for advice on
molecular modeling, and Juliana Chang and Derek Greene for critically
reading the manuscript.
Author Contributions
Conceived and designed the experiments: NH IMS. Performed the
experiments: NH IMS. Analyzed the data: NH IMS. Contributed
reagents/materials/analysis tools: NH IMS. Wrote the paper: NH IMS.
References
1. Delmas P, Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7)
potassium channels. Nat Rev Neurosci 6: 850–862.
2. Marrion NV (1997) Control of M-current. Annu Rev Physiol 59: 483–504.
3. Higashida H, Brown DA (1986) Two polyphosphatidylinositide metabolites
control two K+ currents in a neuronal cell. Nature 323: 333–335.
4. Hoshi N, Zhang JS, Omaki M, Takeuchi T, Yokoyama S, et al. (2003)
AKAP150 signaling complex promotes suppression of the M-current by
muscarinic agonists. Nat Neurosci 6: 564–571.
5. Hoshi N, Langeberg LK, Scott JD (2005) Distinct enzyme combinations in
AKAP signalling complexes permit functional diversity. Nat Cell Biol 7:
1066–1073.
6. Bosma MM, Hille B (1989) Protein kinase C is not necessary for peptide-induced
suppression of M current or for desensitization of the peptide receptors. Proc
Natl Acad Sci U S A 86: 2943–2947.
7. Suh BC, Hille B (2002) Recovery from muscarinic modulation of M current
channels requires phosphatidylinositol 4,5-bisphosphate synthesis. Neuron 35:
507–520.
8. Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD (2010) Interaction
with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell 37:
541–550.
9. Xu ZB, Chaudhary D, Olland S, Wolfrom S, Czerwinski R, et al. (2004)
Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). J Biol
Chem 279: 50401–50409.
10. Messerschmidt A, Macieira S, Velarde M, Badeker M, Benda C, et al. (2005)
Crystal structure of the catalytic domain of human atypical protein kinase C-iota
reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 352:
918–931.
11. Grodsky N, Li Y, Bouzida D, Love R, Jensen J, et al. (2006) Structure of the
catalytic domain of human protein kinase C beta II complexed with a
bisindolylmaleimide inhibitor. Biochemistry 45: 13970–13981.
12. Leonard TA, Rozycki B, Saidi LF, Hummer G, Hurley JH. Crystal structure
and allosteric activation of protein kinase C betaII. Cell 144: 55–66.
13. Kemp BE, Parker MW, Hu S, Tiganis T, House C (1994) Substrate and
pseudosubstrate interactions with protein kinases: determinants of specificity.
Trends Biochem Sci 19: 440–444.
14. House C, Kemp BE (1987) Protein kinase C contains a pseudosubstrate
prototope in its regulatory domain. Science 238: 1726–1728.
15. Newton AC (2001) Protein kinase C: structural and spatial regulation by
phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101:
2353–2364.
16. Zhu G, Fujii K, Liu Y, Codrea V, Herrero J, et al. (2005) A single pair of acidic
residues in the kinase major groove mediates strong substrate preference for P-2
or P-5 arginine in the AGC, CAMK, and STE kinase families. J Biol Chem 280:
36372–36379.
17. Gallegos LL, Kunkel MT, Newton AC (2006) Targeting protein kinase C
activity reporter to discrete intracellular regions reveals spatiotemporal
differences in agonist-dependent signaling. J Biol Chem 281: 30947–30956.
18. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, et al. (1991) The
bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein
kinase C. J Biol Chem 266: 15771–15781.
19. Eichholtz T, de Bont DB, de Widt J, Liskamp RM, Ploegh HL (1993) A
myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol
Chem 268: 1982–1986.
20. Herberg FW, Doyle ML, Cox S, Taylor SS (1999) Dissection of the nucleotide
and metal-phosphate binding sites in cAMP-dependent protein kinase.
Biochemistry 38: 6352–6360.
21. Kim C, Xuong NH, Taylor SS (2005) Crystal structure of a complex between
the catalytic and regulatory (RIalpha) subunits of PKA. Science 307: 690–696.
22. Zimmermann B, Schweinsberg S, Drewianka S, Herberg FW (2008) Effect of
metal ions on high-affinity binding of pseudosubstrate inhibitors to PKA.
Biochem J 413: 93–101.
23. Bornancin F, Parker PJ (1997) Phosphorylation of protein kinase C-alpha on
serine 657 controls the accumulation of active enzyme and contributes to its
phosphatase-resistant state. J Biol Chem 272: 3544–3549.
24. Steyer JA, Almers W (2001) A real-time view of life within 100 nm of the plasma
membrane. Nat Rev Mol Cell Biol 2: 268–275.
25. Violin JD, Zhang J, Tsien RY, Newton AC (2003) A genetically encoded
fluorescent reporter reveals oscillatory phosphorylation by protein kinase C.
J Cell Biol 161: 899–909.
26. Yeh JZ, Armstrong CM (1978) Immobilisation of gating charge by a substance
that simulates inactivation. Nature 273: 387–389.
27. Hille B (2001) Ion channels of excitable membranes. SunderlandMass: Sinauer.
814 p.
28. Faux MC, Rollins EN, Edwards AS, Langeberg LK, Newton AC, et al. (1999)
Mechanism of A-kinase-anchoring protein 79 (AKAP79) and protein kinase C
interaction. Biochem J 343: 443–452.
29. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, et al. (1991) Antagonist
binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol
Exp Ther 256: 727–733.
State-Dependent Inhibition of ATP Competitors
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26338